-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 5, Betta Pharmaceuticals issued an announcement stating that the company's application for clinical trials of BPI-361175 tablets has been approved by the US FDA and is intended to be used for the treatment of non-small cell lung cancer carrying EGFRC797S mutations and other EGFR-related mutations
BPI-361175 is a new molecular entity with completely independent intellectual property rights independently developed by Betta Pharmaceuticals.
In February 2021, the company obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration on BPI-361175 tablets
As of the disclosure date of this announcement, domestic and foreign drugs targeting EGFRC797S mutations are in preclinical
Or in the early clinical stage, there is no drug on the market